Daehwa Pharmaceutical
1
146M
1
0.03
- Areas of investment
Summary
Daehwa Pharmaceutical is the famous Corporate Investor, which was founded in 1984. The fund was located in Asia if to be more exact in South Korea. The main office of represented Corporate Investor is situated in the Seoul.
The fund is constantly included in less than 2 deals per year. The top activity for fund was in 2019. Deals in the range of more than 100 millions dollars are the general things for fund.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. Among the most successful fund investment fields, there are Biopharma, Biotechnology. Among the various public portfolio startups of the fund, we may underline Haihe Biopharma Besides, a startup needs to be aged 6-10 years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 9 partakers. The meaningful sponsors for the fund in investment in the same round are Yingke Capital, Huagai Capital, Hillhouse Capital Group.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.03
- Investments by industry
- Pharmaceutical (1)
- Medical (1)
- Health Care (1)
- Biopharma (1)
- Biotechnology (1)
- Investments by region
-
- China (1)
- Peak activity year
- 2019
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 1B
- Group Appearance index
- 1.00
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Haihe Biopharma | 11 Feb 2019 | Biotechnology, Health Care, Medical, Pharmaceutical, Biopharma | Early Stage Venture | 146M | China, Shanghai |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.